Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUSTAIN 1: Semaglutide Monotherapy in T2D
NCT02054897Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2014
- Primary completion
- May 2015
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in Glycosylated Haemoglobin at 30 weeks. Started Feb 2014; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02054897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02054897.